Fig. 4

In vivo biodistribution and liver targeting profiles of MLNPs. (a) Stabilities of MLNPs in the simulated gastric, small intestinal, and colonic fluids. (b) Ex vivo fluorescence images of the GIT in the HCC mouse model receiving oral administration of DiR-MLNPs at different time points (12, 24, 48, and 72 h). (c) Ex vivo tumor-targeted fluorescence images and bio-distribution of DiR-labeled MLNPs in the orthotopic liver cancer mouse model. (d) Fluorescence images of the GIT sections from mice receiving oral administration of DiO-MLNPs (Scale bar = 100 μm). Each point represents the mean ± S.E.M. (n = 3)